Biopharmaceutical company developing therapies for neurological diseases and rare disorders.
Biohaven Pharmaceutical Holding Company Ltd., a dynamic clinical-stage biopharmaceutical firm headquartered in New Haven, Connecticut, focuses on pioneering therapies for patients grappling with severe neurological and neuropsychiatric conditions across the United States. The company's robust pipeline includes BHV-7000, an innovative potassium channel activator designed to address focal epilepsy. Additionally, Biohaven is advancing Troriluzole, a tripeptide prodrug currently in Phase 3 clinical trials targeting a spectrum of neurological and neuropsychiatric disorders.
Among its promising developments is BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist engineered to alleviate neuropathic pain. The company also spearheads Verdiperstat, an irreversible myeloperoxidase enzyme inhibitor aimed at treating various neurodegenerative diseases. Furthermore, Biohaven offers Taldefgrobep Alfa, an anti-myostatin adnectin currently in Phase 3 clinical trials for spinal muscle atrophy, and BHV-1100, undergoing Phase 1a/1b clinical trials for multiple myeloma patients.
Originally founded as Biohaven Research Ltd., the company rebranded to Biohaven Ltd. in September 2022. Biohaven Pharmaceutical Holding Company Ltd. was established with a mission to innovate therapeutic solutions that significantly improve patient outcomes. Through strategic research initiatives and robust clinical trials, Biohaven remains committed to advancing groundbreaking treatments for complex medical challenges.
As a subsidiary of Biohaven Pharmaceutical Holding Company Ltd., Biohaven Ltd. leverages its parent company's expertise and resources to drive forward its ambitious research and development agenda. The company's commitment to scientific excellence and patient-centric innovation underscores its role as a leader in the biopharmaceutical industry, poised to redefine standards of care in neurology and psychiatry.